Document Detail

Effect of L-thyroxine replacement on apolipoprotein B-48 in overt and subclinical hypothyroid patients.
MedLine Citation:
PMID:  22986485     Owner:  NLM     Status:  MEDLINE    
Apolipoprotein B-48 (ApoB-48) is a constituent of chylomicrons and chylomicron remnants, and is thought to be one of the risk factors for atherosclerosis. We evaluated the effect of L-thyroxine (L-T(4)) replacement on serum ApoB-48 levels in patients with primary hypothyroidism. Eighteen patients with overt hypothyroidism (OH) and 18 patients with subclinical hypothyroidism (SH) participated in the study. The lipid profiles, including ApoB-48, were measured in patients with hypothyroidism before and 3 months after L-T(4) replacement. After L-T(4) replacement, the serum concentrations of all lipoproteins, exclusive of lipoprotein(a) (Lp(a)), were significantly decreased in patients with OH. In patents with SH, the serum levels of total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL-C), remnant-like particle cholesterol (RLP-C), apolipoprotein B (ApoB), and ApoB-48 decreased significantly after L-T(4) replacement. The serum levels of triglycerides (TG), HDL-C, low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (ApoA-1), and Lp(a) did not change significantly. In all 36 patients, the reduction in the ApoB-48 levels correlated significantly with the reduction in TSH levels (r = 0.39, P<0.05). This study showed clearly that L-T(4) replacement might reduce serum levels of ApoB-48 in both OH and SH patients. Such altered serum levels of ApoB-48 in patients with OH and SH may be related to the disturbed metabolism of chylomicron remnants in patients with hypothyroidism.
Mitsuru Ito; Akira Kitanaka; Takeshi Arishima; Takumi Kudo; Eijun Nishihara; Sumihisa Kubota; Nobuyuki Amino; Tetsuya Hiraiwa; Toshiaki Hanafusa; Akira Miyauchi
Related Documents :
23269345 - Bdnf val66met homozygosity does not influence plasma bdnf levels in healthy human subje...
23670065 - Bioavailability of l-thyroxine and its metabolites after topical treatment with an emul...
24149975 - Serum tcdd and teq concentrations among seveso women, 20 years after the explosion.
323975 - Serum complement-like opsonic activities in human, animal, vegetable, and proprietary m...
19501415 - Serum interleukin-6 (il-6) and il-10 concentrations in normal and septic neonatal foals.
25158005 - Evidence for disturbed insulin and growth hormone signaling as potential risk factors i...
Publication Detail:
Type:  Journal Article     Date:  2012-10-15
Journal Detail:
Title:  Endocrine journal     Volume:  60     ISSN:  1348-4540     ISO Abbreviation:  Endocr. J.     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-31     Completed Date:  2013-07-22     Revised Date:  2014-11-10    
Medline Journal Info:
Nlm Unique ID:  9313485     Medline TA:  Endocr J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  65-71     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apolipoprotein B-48 / blood*
Hypothyroidism / blood,  drug therapy*
Lipids / blood
Middle Aged
Severity of Illness Index
Thyroxine / blood,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Apolipoprotein B-48; 0/Lipids; Q51BO43MG4/Thyroxine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Correlation between Protective Immunity to ?-Synuclein Aggregates, Oxidative Stress and Inflammation...
Next Document:  Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver [Review...